This study was undertaken to evaluate the biological potency of two synthetic human growth hormone-releasing factors, hGRF (1-44)NH2 and hGRF (1-29)NH2, on growth hormone (GH) release in young dairy heifers (n = 10) and pigs (n = 10). In each species, the GH response to an iv injection (0, .067, .2, .6 and 1.8 nmol.kg-1 body weight) of each peptide was evaluated in a double 5 X 5 Latin square d...

new chemical drugs in Sweden. Recommendations were based on clinical comparability and lower drug acquisition costs, for the biosimilars versus the originator, and for lipegfilgrastim versus pegfilgrastim. Use of the pegylated forms of filgrastim appear to be restricted to certain situations where their use is considered appropriate. Wales:12 The biosimilars and the pegylated forms of filgrasti...

In 2006, the European Medicines Agency (EMA) approved Omnitrope® as a biosimilar recombinant human growth hormone (rhGH), on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin®, Pfizer). Data continue to be collected on the long-term efficacy of biosimilar rhGH from several on-going postapproval studies. Particular topics of interest include efficacy in ...

BACKGROUND Mathematical models can be used to predict individual growth responses to growth hormone (GH) therapy. The aim of this study was to construct and validate high-precision models to predict the growth response to GH treatment of short children, independent of their GH status, birth size and gestational age. As the GH doses are included, these models can be used to individualize treatme...

dream of Olympic glory, and for the few who achieve professional success there are notable financial rewards. It is perhaps unsurprising that there is a strong temptation to enhance performance pharmacologically in both professional and amateur sports, and growth hormone (GH) is well recognised as a drug of abuse. This is particularly the case among weightlifters, where it is typically used in ...

Growth hormone (GH) and prolactin (PRL) in maternal and fetal serum and amniotic fluid were measured simultaneously by radioimmunoassay at term deliveries of 20 normal mothers. The PRL level of amniotic fluid was significantly higher than that of maternal and fetal serum. The fetal GH level was significantly higher than the maternal and amniotic levels of GH. There was no significant correlatio...

BACKGROUND Responsiveness to GH treatment can be estimated by both growth and ∆IGF-I. The primary aim of the present study was to investigate if mimicking the physiological increase during puberty in GH secretion, by using a higher GH dose could lead to pubertal IGFs in short children with low GH secretion. The secondary aim was to explore the relationship between IGF-I, IGFBP-3 and the IGF-I/I...